Table 2.
Ghrelin and GHS-R Type 1a and 1b Expression in Normal Thyroid and Follicular-Derived Tumors
| Diagnosis (total cases) | M/F | Mean age (years) | Ghrelin | GHS-R1a RT-PCR | GHS-R1b RT-PCR | NR-ISGB | ||
|---|---|---|---|---|---|---|---|---|
| ICC | In situ hybridization | RT-PCR | ||||||
| NT (10) | 4/6 | 51 | 0/10 | 0/5 | 3/5 | 0/5 | 1/5 | 2/3 |
| FA (18) | 8/10 | 47.3 | 13/18 | 5/11 | 9/12 | 0/12 | 0/12 | 6/6 |
| FC (10) | 3/7 | 52.3 | 9/10 | 6/6 | 4/6 | 0/6 | 0/6 | 1/1 |
| PTC (12) | 5/7 | 39.8 | 9/12 | 6/9 | 5/10 | 0/10 | 0/10 | 5/5 |
| PDC (8) | 2/6 | 57.5 | 8/8 | 8/8 | 1/1 | 0/1 | 0/1 | 0/2 |
| AC (6) | 2/4 | 58.6 | 3/6 | 3/4 | 2/4 | 0/4 | 0/4 | 2/2 |
M, male; F, female; ICC, immunocytochemistry; NR-ISGB, nonradioactive in situ localization of ghrelin binding; NT, normal thyroid; FA, follicular adenoma; PTC, papillary thyroid carcinoma; FCC, follicular carcinoma; PDC, poorly differentiated carcinoma; AC, anaplastic carcinoma.